Antibody-Drug Conjugates (ADCs) Market Size to Reach USD 20.01 Billion in 2028 | Increasing Prevalence of Cancer Along with Growing Geriatric Population are Significant Factor Driving Industry Demand, says Emergen Research

VANCOUVER, BC, Sept. 27, 2021 /PRNewswire/ -- The global Antibody-Drug Conjugates market size is expected to reach USD 20.01 Billion at a steady revenue CAGR of 25.8% in 2028, according to latest analysis by Emergen Research. Surge in research activities on preclinical research, antibody therapies, and advanced drug discoveries are some key factors driving antibody-drug conjugates market revenue growth.

A primary benefit of ADC is to improve therapeutic index of antineoplastic agents. Advancements in synthetic biochemistry have ushered in new generations of ADCs, which show promise to enhance cytotoxicity of tissue and specificity to a better extent than predecessors. Advantages of ADCs are an increase in cell-killing potential of monoclonal antibodies, limited systemic exposure, higher tumor selectivity, and increase in drug tolerability. ADCs work like 'smart bombs' against cancer cells. These drugs are composed of an antibody drug, cytotoxic chemotherapy drug, and a linker. By targeting cancer cells particularly, healthy exposure of healthy cells to toxic cancer drug is greatly reduced.

ADCs in combination with other therapy and drugs is an emerging concept and various companies are adopting ADC, which is expected to drive steady growth of the market in the long term. High cost of procedure and lack of fund act as restraints to market growth. Producing ADCs is quite complex, which also a factor serving as a restraint. ADC facilities require extensively specialized training for operators and high capital investment.

Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/754

Some Key Highlights From the Report

• In July 2021, Innovent Biologics, Inc. announced signing of target-specific, non-exclusive license agreement with Synaffix B.V. The latter will provide all the required proprietary ADC technologies to enable Innovent to progress one of its antibodies as the best-in-class ADC candidate.
• Cleavable linker segment revenue is expected to expand at a rapid rate during the forecast period as cleavage linker plays an important role in success of ADCs. These are stable in blood circulation for longer period of time and have also emerged as a targeted drug delivery agent and BR96-Doxorubicin (BR96-Dox) is an excellent example of cleavable linker.
• Blood cancer is among the most common and lethal cancers among adults and ADCs are being developed across the globe as a major strategy to combat the disease. Several ADCs have been approved for clinical use. Treatment options of blood cancer have grown exponentially beyond general chemotherapy, with development of new targeted therapies.
• Hospital segment accounted for a significantly larger revenue share in 2020 as majority of hospitals treat cancer with the help of ADCs. Hospitals provide advanced drugs and therapies that can treat cancer cells without compromising on healthy cells. Surge in number of cancer treatment hospitals across the globe is also driving growth of this segment.
• Market revenue in Asia Pacific is expected to expand at a rapid rate during the forecast period owing to improvements in healthcare infrastructure in countries in the region and rise in supportive initiatives by governments. Rise in prevalence of cancer and emergence of various research institutes is also fueling market revenue growth. High demand from China, Singapore, Japan, and India is also contributing to growth of the Asia Pacific antibody-drug conjugates market.
• Some major players in the global market include Oxford BioTherapeutics, Bayer AG, Immunomedics Inc., Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Pfizer Inc., ImmunoGen Inc., AbbVie Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Make Payment [Buy your Exclusive copy]@ https://www.emergenresearch.com/select-license/754

Emergen Research has segmented the global Antibody-Drug Conjugates (ADCs) market on the basis of technology, application, end-use, and region:

• Technology Outlook (Revenue, USD Billion; 2018–2028)
• Cleavable Linker
• Non-Cleavable Linker
• Application Outlook (Revenue, USD Billion; 2018–2028)
• Blood Cancer
• Leukemia
• Lymphoma
• Brain Tumor
• Ovarian Cancer
• Breast Cancer
• Lung Cancer
• Others
• End-use Outlook (Revenue, USD Billion; 2018–2028)
• Hospitals
• Research Institute
• Clinics

Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/antibody-drug-conjugates-market

• Regional Outlook (Revenue, USD Billion; 2018–2028)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Spain
• BENELUX
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Rest of LATAM
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• Rest Of MEA

Explore More Reports offered by Emergen Research:

The global Healthcare Internet of Things (IoT) security market size is expected to reach USD 5.52 Billion in 2028 and register a revenue CAGR of 21.6% during the forecast period. Rising concerns regarding security of critical infrastructure in the healthcare sector is a key factor driving global healthcare Internet of Things (IoT) security market revenue growth.

The global clinical trial software market size reached USD 900.3 Million in 2020 and is expected to register a revenue CAGR of 15.6% during the forecast period. Rising global prevalence of infectious, chronic, and rare diseases is a key factor expected to continue to drive global clinical trial software market revenue growth over the forecast period.

The global CRISPR/CAS 9 technology market size is expected to reach USD 6,221 Million in 2028 and register a revenue CAGR of 20.4% during the forecast period. Global CRISPR/CAS 9 technology market revenue growth is driven by the fact that it currently is the simplest and most versatile, as well as precise method of genetic manipulation and rising support for research and increasing government and private funding.

The global AI-based clinical trials solution provider market size reached USD 1.24 Billion in 2020 and is expected to register a revenue CAGR of 21.5% during the forecast period. Increasing adoption of AI-enabled digital health technology is a key factor expected to drive global AI-based clinical trials solution provider market revenue growth over the forecast period.

The global functional ingredients market size reached USD 67.94 Billion in 2020 and is expected to register a revenue CAGR of 6.3% during the forecast period. Increasing consumption of nutritious convenience and fortified foods, rising demand for nutraceuticals for disease risk reduction, and increasing demand for functional ingredients in personal care products and pharmaceuticals are key factors expected to drive market revenue growth to a significant extent over the forecast period.

About Emergen Research 

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Custom Intelligence services | Growth Consulting Services
Facebook | LinkedIn | Twitter | Blogs
Read Full Press Release@ https://www.emergenresearch.com/press-release/global-antibody-drug-conjugates-market

Logo: https://mma.prnewswire.com/media/1579538/Emergen_Research_Logo.jpg